^
BIOMARKER:

CCDC6-RET fusion

i
Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1, CCDC6, Coiled-Co
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
CCDC6-RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CCDC6-RET fusion
Non Small Cell Lung Cancer
RET inhibitor
Sensitive
:
C3
CCDC6-RET fusion
Non Small Cell Lung Cancer
vandetanib
Sensitive
:
C3
CCDC6-RET fusion
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
C3
CCDC6-RET fusion
Colorectal Cancer
RXDX-105
Sensitive
:
C3
CCDC6-RET fusion
Non Small Cell Lung Cancer
sunitinib
Sensitive
:
C3
CCDC6-RET fusion
Non Small Cell Lung Cancer
nintedanib
Sensitive
:
C3
CCDC6-RET fusion
Non Small Cell Lung Cancer
cabozantinib capsule
Sensitive
:
C3
CCDC6-RET fusion
Non Small Cell Lung Cancer
lenvatinib
Sensitive
:
C3
CCDC6-RET fusion
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive
:
C4
CCDC6-RET fusion
Non Small Cell Lung Cancer
RXDX-105
Sensitive
:
D
CCDC6-RET fusion
Lung Adenocarcinoma
cabozantinib capsule
Sensitive
:
D